Ropes & Gray, the global law firm, represented TPG Growth and Michael Xin Hui in their effort to take private ShangPharma, a China-based contract research organization. Hui is ShangPharma’s CEO. The deal closed on Wednesday.
Ropes & Gray represented the buyer group consortium of TPG Growth and ShangPharma’s CEO, Michael Xin Hui, ShangPharma’s going private transaction, which closed March 27.
ShangPharma is a leading, China-based contract research organization.
The transaction is just the second private equity sponsor-backed going-private transaction of a China-based, NYSE or NASDAQ listed company to sign and close since the beginning of 2012.
The Ropes & Gray team advising the buyer group and TPG is led by Asia-based partners Scott Jalowayski and Paul Boltz.